- History of high blood pressure, controlled with an ACE inhibitor
- Presents to primary care physician with worsening abdominal pain, blood in stool, constipation, and fatigue
- A colonoscopy confirmed a 3.5 cm, non-obstructing left-sided colon tumor
- ECOG PS 1
- PET scan shows liver metastases
- Tumor was found to be KRAS wild-type, EGFR-expressing
- Next generation sequencing found no RAS mutations
- Surgical consultation determined metastases are borderline resectable
- Recommend reevaluation after systemic therapy
- Surgeon’s treatment goal is to downstage the tumor for future surgical evaluation
*A hypothetical patient case study.
ECOG=Eastern Cooperative Oncology Group; EGFR=epidermal growth factor receptor; FOLFIRI=irinotecan, 5-fluorouracil, and leucovorin; mCRC=metastatic colorectal cancer; PET=positron emission tomography; PS=performance status.
ERBITUX combination therapy may be right for this patient.